Apogee Therapeutics, Inc. APGE Proceeds From Issuance Of Common Stock Under The At The Market Net Of Issuance Costs
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept apge:ProceedsFromIssuanceOfCommonStockUnderTheAtTheMarketNetOfIssuanceCosts.
The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Apogee Therapeutics, Inc.'s proceeds from issuance of common stock under the at the market net of issuance costs.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Apogee Therapeutics, Inc.'s proceeds from issuance of common stock under the at the market net of issuance costs?
- Apogee Therapeutics, Inc. (APGE) reported proceeds from issuance of common stock under the at the market net of issuance costs of $28.93M in Q1 2026.